Arcellx (ACLX) Receivables (2022 - 2023)

Arcellx's (ACLX) quarterly Receivables came in at $33.5 million in Q3 2023, down 10.78% quarter-over-quarter from $37.6 million in Q2 2023.

Arcellx (ACLX) Receivables (2022 - 2023) Analysis & Trends

Arcellx's Receivables history runs 2 years deep, the most recent figure standing at $33.5 million for Q3 2023.

On a quarterly basis, Receivables changed N/A year-over-year to $33.5 million in Q3 2023; TTM through Sep 2023 was $33.5 million, a N/A change from a year earlier, with the FY2022 full-year figure at $2.0 million, changed N/A from the prior year.
Receivables eased to $33.5 million in Q3 2023 per ACLX's latest filing, from $37.6 million in the prior quarter.
Across five years, Receivables topped out at $37.6 million in Q2 2023 and bottomed at $2.0 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	4.97 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	938.02 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	1.13 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	2.00 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	5.73 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	1.93 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Arcellx	6.48 Bn	6.48 Bn	-	-

Download Data